Curis, Inc. (CRIS)
| Market Cap | 732.15M |
| Revenue (ttm) | 11.10M |
| Net Income (ttm) | -31.00M |
| Shares Out | 54.55M |
| EPS (ttm) | -0.77 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $9.47 |
| Previous Close | $9.13 |
| Change ($) | 0.34 |
| Change (%) | 3.72% |
| Day's Open | 9.07 |
| Day's Range | 8.25 - 9.54 |
| Day's Volume | 1,881,160 |
| 52-Week Range | 0.62 - 13.44 |
LEXINGTON, Mass., Feb. 19, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today ann...
Quick overview of Curis and stock price history. Review on the potential for therapies that target the immune system checkpoint regulator “VISTA” (V-domain immunoglobulin (Ig) suppressor of T ...
LEXINGTON, Mass., Jan. 8, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today anno...
Overview of Curis, including key partnerships, balance sheet, and recent stock price. Review of Non-Hodgkin's Lymphoma, Myelodysplastic Syndromes and Acute Myeloid Leukemia. Patient need, curr...
Small Cap Momentum Stories to Watch (NASDAQ: BLNK) (OTC US: MMEDF) (OTC US: CLKA) (NASDAQ: CRIS)
Curis (CRIS) saw a big move last session, as its shares jumped 5% on the day, amid huge volumes.
Curis Inc. (NASDAQ: CRIS) shares are on the run again.
LEXINGTON, Mass., Dec. 9, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today annou...
Curis' (CRIS) hematologic malignancy candidate, CA-4948, shows promising activity in early-stage studies evaluating it in patients with either acute myeloid leukemia or non-Hodgkin's lymphoma....
The stock price of Curis, Inc. (NASDAQ: CRIS) increased by 354.86% as it went from a previous close of $1.44 to $6.55 per share today. This is why it happened.
Curis, Inc. staged an eye-popping rally on Tuesday after it released positive preliminary data related to its phase one trial of CA-4948, a small molecule inhibitor that is being tested in pat...
Curis, Inc. (NASDAQ: CRIS) shares were skyrocketing Tuesday on above-average volume after the company announced updated Phase 1 data on its investigational asset CA-4948 in treating acute myel...
Curis (CRIS) stock is taking off on Tuesday following news of positive preliminary data from a Phase 1 clinical trial for its leukemia drug. The post CRIS Stock News: Why Biotech Stock Play Cu...
After Curis Inc. (NASDAQ: CRIS) announced preliminary data from its ongoing early-stage study in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS), its sh...
Shares of Curis Inc. more than tripled Tuesday, to lead all premarket gainers and with the most volume, after the biotechnology company announced positive preliminary data from a Phase 1 study...
LEXINGTON, Mass., Dec. 7, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today anno...
Curis, Inc. (CRIS) CEO Jim Dentzer on Q3 2020 Results - Earnings Call Transcript
Curis, Inc. (CRIS) CEO Jim Dentzer On Q3 2020 Results - Quick Version Earnings Call Transcript
Shares of Curis (NASDAQ:CRIS) fell 0.88% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 42.11% year over year to ($0.11), which b...
LEXINGTON, Mass., Nov. 4, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today anno...
LEXINGTON, Mass., Nov. 4, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today anno...
LEXINGTON, Mass., Oct. 21, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today hig...
LEXINGTON, Mass., Oct. 14, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today ann...
Curis, Inc. (CRIS) CEO Jim Dentzer on Q2 2020 Results - Earnings Call Transcript
LEXINGTON, Mass., June 11, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today ann...
Shares of nano-cap biopharma Curis, Inc. (NASDAQ: CRIS) are on a strong two-day run that has lifted the equity from penny stock territory.
Curis Inc. (NASDAQ: CRIS) shares jumped on Wednesday after the company announced that the U.S.
Curis, Inc. (CRIS) CEO Jim Dentzer on Q1 2020 Results - Earnings Call Transcript
Curis Inc.'s (CRIS) CEO James Dentzer on Q4 2019 Results - Earnings Call Transcript
Curis Inc.'s (CRIS) CEO James Dentzer on Q3 2019 Results - Earnings Call Transcript
Curis' (CRIS) CEO Jim Dentzer on Q2 2019 Results - Earnings Call Transcript
Curis, Inc. (CRIS) CEO Jim Dentzer on Q1 2019 Results - Earnings Call Transcript
Curis, Inc. (CRIS) CEO Jim Dentzer on Q4 2018 Results - Earnings Call Transcript
Thinly traded Curis, Inc. shares weremoving notably higher Monday on roughly 35 times their average volume.
Curis' stock rockets on heavy volume after $135.7 million deal to sell portion of Erivedge royalties
Shares of Curis, Inc. rocketed 93% in very active premarket trade Monday.
About CRIS
Curis, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation; and Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for ... [Read more...]
| Industry Biotechnology | IPO Date Aug 1, 2000 |
| CEO James Dentzer | Employees 28 |
| Stock Exchange NASDAQ | Ticker Symbol CRIS |
Financial Performance
In 2019, Curis, Inc.'s revenue was $10.00 million, a decrease of -4.07% compared to the previous year's $10.43 million. Losses were -$32.14 million, -1.33% less than in 2018.
Analyst Forecasts
According to 3 analysts, the average rating for Curis, Inc. stock is "Buy." The 12-month stock price forecast is 15.75, which is an increase of 66.31% from the latest price.